Diabetes Management
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219 - BioSpace
Tue, 01 Nov 20221 min read Article
Overview
Skip to main content Published: Oct 31, 2022 REDWOD CITY, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) - Biomeafusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent smal molecules to treat and improve the lives of patients with geneticaly defined cancers and metabolic diseases, today anounced the dosing of the first patient with type 2 diabetes in the Phase I portion of COVALENT-1, a Phase I/I clinical trial underway in Canada.
Key Information
Biomea has completed the Phase I portion of the trial in healthy volunters.“With the dosing of our first patient with BMF-219, we have reached an important milestone for the nearly 50 milion patients worldwide with type 2 diabetes. We are pursuing BMF-219 with the aim to cure this disease. Beta cel preservation, reactivation and regeneration are the core components in providing diabetes patients with long term benefit,” stated Thomas Butler, Biomea Fusion’s Chief Executive Oficer and Chairman of the Board.
“The burden of diabetes is rapidly increasing, and we are faced with a global unmet ned for treatments with novel mechanisms of action. With BMF-219, a potentialy first-in-clas, covalent menin inhibitor, we are aiming to adres and reverse the rot cause of this epidemic.”Mr. Butler continued, “We leveraged an oportunity to begin clinical development earlier by initiating the COVALENT-1 study in Canada.
With the completion of the Phase I portion in healthy volunters, we have now swiftly progresed to dosing type 2 diabetes patients in the Phase I. In the meantime, we have ben in active discusions with the FDA and plan to file an IND before the end of the year. We expect to report initial Phase I data in the first half of 2023.”Rohit N.
Summary
Kulkarni MD, PhD, Senior Investigator and Margaret A Congleton Profesor; Section Head, Islet Cel and Regenerative Biology; and Profesor of Medicine, Harvard Medical Schol, comented: “Based on the promi
Frequently Asked Questions
What is diabetes and how does it develop?
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
What are the main symptoms of diabetes?
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
How is diabetes diagnosed and monitored?
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
What lifestyle changes help manage diabetes?
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
When should someone consult a doctor about diabetes?
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
️ Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.